Reviewer’s report

Title: Valproic Acid Sensitizes Metformin-resistant Human Renal Cell Carcinoma Cells by Upregulating H3 Acetylation and EMT Reversal

Version: 0 Date: 25 Oct 2017

Reviewer: Ekta Khattar

Reviewer's report:

1. The scientific writing and grammar needs tremendous improvement.

2. In figure 8, vpa+metformin is not mentioned in the text.

3. In Figure 2c and 3d, single time points are captured for cell cycle analysis. So it is difficult to say whether it is arrest or changes in cell division rates. It would be better to show at least two time points to understand the cell cycle status.

4. In Figure 7d the positive control for rapamycin treatment which is its target S6K phosphorylation should be checked to ensure that drug is working.

5. In figure 7d SC79 does not seem to increase Akt phosphorylation significantly. Please describe accordingly in the text section.

6. In discussion, line 294 states normal RCC cell lines. Please rewrite this as RCC cell lines. You cannot write normal.
Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

No

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

No

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

Quality of written English
Please indicate the quality of language in the manuscript:

Not suitable for publication unless extensively edited

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?
If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal